• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Calu-3 肺上皮细胞系的药物应用。

Pharmaceutical applications of the Calu-3 lung epithelia cell line.

机构信息

Woolcock Institute of Medical Research, Respiratory Technology, Glebe, NSW, Australia.

出版信息

Expert Opin Drug Deliv. 2013 Sep;10(9):1287-302. doi: 10.1517/17425247.2013.805743. Epub 2013 Jun 4.

DOI:10.1517/17425247.2013.805743
PMID:23730924
Abstract

INTRODUCTION

The Calu-3 lung cell line has been shown to be a promising in vitro model of airway epithelia due to its similarity to in vivo physiology. Hence, over the past decade, it has found increasing applications in the pharmaceutical industry.

AREAS COVERED

This review focuses on the pharmaceutical applications of the Calu-3 cell line in areas such as mechanisms of drug transport, studying aerosol deposition, controlled release studies and identification of possible drug-drug interactions. The main findings of various studies, as well as the predictive potential of this model, are presented and discussed in this review.

EXPERT OPINION

There is still a lack of mechanistic knowledge regarding transport of inhaled therapeutics across the lungs. Cell culture models such as Calu-3 provide a simple and reproducible system to study the underlying mechanisms by which inhaled therapeutics interact with the lungs. However, more complex systems that integrate particle deposition onto different cell culture systems may be useful in addressing some fundamental questions to generate a better understanding of determinants that influences pulmonary drug dissolution, absorption, metabolism and efficacy. Ultimately the use of the Calu-3 cell line provides a basic research tool that enables the development of safer and more effective inhaled therapeutics.

摘要

简介

Calu-3 肺细胞系因其与体内生理学的相似性,已被证明是一种有前途的气道上皮体外模型。因此,在过去的十年中,它在制药行业中的应用越来越广泛。

涵盖领域

本文综述了 Calu-3 细胞系在药物转运机制、气溶胶沉积研究、控释研究和潜在药物相互作用识别等领域的药物应用。本文介绍和讨论了各种研究的主要发现以及该模型的预测潜力。

专家意见

对于吸入治疗药物在肺部的转运机制,我们仍缺乏相关的知识。Calu-3 等细胞培养模型为研究吸入治疗药物与肺部相互作用的潜在机制提供了一个简单且可重复的系统。然而,更复杂的系统,如将颗粒沉积到不同的细胞培养系统中,可能有助于解决一些基本问题,从而更好地了解影响肺部药物溶解、吸收、代谢和疗效的决定因素。最终,Calu-3 细胞系的使用提供了一个基础研究工具,使更安全、更有效的吸入治疗药物的开发成为可能。

相似文献

1
Pharmaceutical applications of the Calu-3 lung epithelia cell line.Calu-3 肺上皮细胞系的药物应用。
Expert Opin Drug Deliv. 2013 Sep;10(9):1287-302. doi: 10.1517/17425247.2013.805743. Epub 2013 Jun 4.
2
Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3.人呼吸道上皮细胞系Calu-3的药物转运与代谢特性
J Control Release. 2003 Feb 21;87(1-3):131-8. doi: 10.1016/s0168-3659(02)00356-5.
3
In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery.用于评估吸入性治疗药物全身递送的肺部吸收和处置的体内、体外和离体模型。
Adv Drug Deliv Rev. 2006 Oct 31;58(9-10):1030-60. doi: 10.1016/j.addr.2006.07.012. Epub 2006 Aug 15.
4
A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations.一种用于细胞培养物的新型药物气溶胶沉积装置(PADDOCC),用于评估计量干粉制剂的肺部药物吸收。
Eur J Pharm Biopharm. 2011 Jan;77(1):132-8. doi: 10.1016/j.ejpb.2010.10.003. Epub 2010 Oct 14.
5
Assessment methods of inhaled aerosols: technical aspects and applications.吸入气雾剂的评估方法:技术层面与应用
Expert Opin Drug Deliv. 2009 Sep;6(9):941-59. doi: 10.1517/17425240903117244.
6
Across the pulmonary epithelial barrier: Integration of physicochemical properties and human cell models to study pulmonary drug formulations.穿越肺上皮屏障:将物理化学性质和人体细胞模型整合起来研究肺部药物制剂
Pharmacol Ther. 2014 Dec;144(3):235-52. doi: 10.1016/j.pharmthera.2014.05.003. Epub 2014 May 15.
7
Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs.实验和机制计算模型在理解吸入性药物肺部暴露方面的进展。
Eur J Pharm Sci. 2018 Feb 15;113:41-52. doi: 10.1016/j.ejps.2017.10.030. Epub 2017 Oct 25.
8
The particle has landed--characterizing the fate of inhaled pharmaceuticals.粒子已经着陆——描述吸入式药物的命运。
J Aerosol Med Pulm Drug Deliv. 2010 Dec;23 Suppl 2:S71-87. doi: 10.1089/jamp.2010.0836.
9
In vivo-in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols.体内-体外相关性:从药物气溶胶预测肺部药物沉积。
J Aerosol Med Pulm Drug Deliv. 2010 Dec;23 Suppl 2:S59-69. doi: 10.1089/jamp.2010.0846.
10
Is the cellular uptake of respiratory aerosols delivered from different devices equivalent?不同设备输送的呼吸道气溶胶的细胞摄取是否相同?
Eur J Pharm Biopharm. 2015 Jun;93:320-7. doi: 10.1016/j.ejpb.2015.04.012. Epub 2015 Apr 27.

引用本文的文献

1
In Vitro and In Vivo Assessment of Pharmacokinetic Profile of Peramivir in the Context of Inhalation Therapy.在吸入疗法背景下对帕拉米韦药代动力学特征的体外和体内评估。
Pharmaceuticals (Basel). 2025 Jan 29;18(2):181. doi: 10.3390/ph18020181.
2
Insights into Inhalation Drug Disposition: The Roles of Pulmonary Drug-Metabolizing Enzymes and Transporters.吸入性药物处置的新视角:肺部药物代谢酶和转运体的作用。
Int J Mol Sci. 2024 Apr 25;25(9):4671. doi: 10.3390/ijms25094671.
3
Toxicological assessment of E-cigarette flavored E-liquids aerosols using Calu-3 cells: A 3D lung model approach.
使用 Calu-3 细胞对电子烟调味电子烟液气溶胶的毒理学评估:一种 3D 肺模型方法。
Toxicology. 2023 Dec;500:153683. doi: 10.1016/j.tox.2023.153683. Epub 2023 Nov 25.
4
SARS-CoV-2 virus-like-particles liposomal reconstitution of spike glycoproteins.严重急性呼吸综合征冠状病毒2型病毒样颗粒 刺突糖蛋白的脂质体重构
Nanoscale Adv. 2023 Jul 14;5(16):4167-4181. doi: 10.1039/d3na00190c. eCollection 2023 Aug 8.
5
Antiviral properties of trans-δ-viniferin derivatives against enveloped viruses.反式-δ-viniferin 衍生物对包膜病毒的抗病毒特性。
Biomed Pharmacother. 2023 Jul;163:114825. doi: 10.1016/j.biopha.2023.114825. Epub 2023 May 4.
6
In Vitro Dissolution and Permeability Testing of Inhalation Products: Challenges and Advances.吸入产品的体外溶出度和渗透性测试:挑战与进展
Pharmaceutics. 2023 Mar 18;15(3):983. doi: 10.3390/pharmaceutics15030983.
7
Model exploration for discovering COVID-19 targeted traditional Chinese medicine.用于发现新冠病毒靶向中药的模型探索
Heliyon. 2022 Dec;8(12):e12333. doi: 10.1016/j.heliyon.2022.e12333. Epub 2022 Dec 10.
8
Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.用于呼吸道 COVID-19 疾病的 RNAi 治疗的纳米颗粒递送平台。
Int J Mol Sci. 2022 Feb 22;23(5):2408. doi: 10.3390/ijms23052408.
9
Applicability of RPMI 2650 and Calu-3 Cell Models for Evaluation of Nasal Formulations.RPMI 2650和Calu-3细胞模型在鼻腔制剂评价中的适用性
Pharmaceutics. 2022 Feb 6;14(2):369. doi: 10.3390/pharmaceutics14020369.
10
Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?用于解决肺部 siRNA 递送至囊性纤维化粘液屏障的杂交脂质/聚合物纳米颗粒:PEG 化是否有区别?
ACS Appl Mater Interfaces. 2022 Feb 16;14(6):7565-7578. doi: 10.1021/acsami.1c14975. Epub 2022 Feb 2.